141103-93-7

Basic information

• Product Name: 4-METHYL-3,4-DIHYDRO-2H-1,4-BENZOXAZINE-7-CARBALDEHYDE
• Synonyms: 4-METHYL-3,4-DIHYDRO-2H-1,4-BENZOXAZINE-7-CARBALDEHYDE;4-METHYL-3,4-DIHYDRO-2H-1,4-BENZOXAZINE-7-CARBOXALDEHYDE;3,4-Dihydro-4-methyl-2H-1,4-benzoxazine-7-carboxaldehyde;3,4-Dihydro-7-formyl-4-methyl-2H-1,4-benzoxazine;4-Methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carbaldehyde;4-Methyl-2,3-dihydro-2H-1,4-benzoxazine-7-carbaldehyde
• CAS NO: 141103-93-7
• Molecular Formula: C₁₀H₁₁NO₂
• Molecular Weight: 177.2
• Mol File: 141103-93-7.mol
• Article Data: 4

Chemical Properties

• Melting Point: 53℃
• Boiling Point: 336.5°Cat760mmHg
• Flash Point: 157.3°C
• Appearance: /
• Density: 1.181g/cm³
• Vapor Pressure: 0.000112mmHg at 25°C
• Refractive Index: 1.587
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.57±0.20(Predicted)
• CAS DataBase Reference: 4-METHYL-3,4-DIHYDRO-2H-1,4-BENZOXAZINE-7-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHYL-3,4-DIHYDRO-2H-1,4-BENZOXAZINE-7-CARBALDEHYDE(141103-93-7)
• EPA Substance Registry System: 4-METHYL-3,4-DIHYDRO-2H-1,4-BENZOXAZINE-7-CARBALDEHYDE(141103-93-7)

Safety Data

• Statements: 36/37/38-52
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 141103-93-7(Hazardous Substances Data)

Usage

General Description

4-METHYL-3,4-DIHYDRO-2H-1,4-BENZOXAZINE-7-CARBALDEHYDE, also known as Melitracen, is a tricyclic antidepressant with sedative properties. It belongs to the class of dibenzoxazepines and is commonly used for the treatment of depression, anxiety disorders, and other mood-related conditions. Melitracen works by inhibiting the reuptake of serotonin and norepinephrine in the brain, leading to an increase in the levels of these neurotransmitters, which in turn helps to improve mood and reduce feelings of anxiety. It is available in various formulations including tablets, capsules, and injections, and is typically prescribed by a healthcare professional. Like other antidepressants, Melitracen may cause side effects such as drowsiness, dizziness, dry mouth, and constipation, and should be used with caution in individuals with a history of seizures, liver or kidney impairment, or certain medical conditions.

InChI:InChI=1/C10H11NO2/c1-11-4-5-13-10-6-8(7-12)2-3-9(10)11/h2-3,6-7H,4-5H2,1H3

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 154264-95-6 7-bromo-4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine 
• 273-53-0 benzoxazole 
• 611-24-5 o-(N-methylamino)phenol 
• 77901-22-5 4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine 

Downstream Products

• 1001088-90-9 (S,E)-2-cyano-3-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(1-phenylethyl)acrylamide 
• 937591-87-2 (4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)(2-phenyl-1,3-dithian-2-yl)methanol 
• 141103-94-8 (4-Methyl-3,4-dihydro-2H-benzo[1,4]oxazin-7-yl)-methanol 

Relevant articles and documents

TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION

Tetracyclic indole derivatives of formula (I), pharmaceutically acceptable salts and the pharmaceutical compositions thereof are provided, wherein A, A', G, R1, R15, U, V, V, W, W, X, X', Y, Y' are as defined in the invention. Use of these derivatives for treating hepatitis C virus (HCV) infection is also provided.

SYNTHESIS AND REACTIONS OF 3,4-DIHYDRO-2H-1,4-BENZOXAZINE DERIVATIVES

Several 3,4-dihydro-2H-1,4-benzoxazine derivatives were prepared from commercially available benzoxazoles by use of an efficient two step sequence.Aryl functionalization reactions allowing access to further benzoxazine derivatives are also described.